Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2000

View Archived Issues

Bioenvision to codevelop clofarabine for leukemia; mode of action examined at UCSD

Proteomics collaboration between Myriad Genetics and Bayer extended and expanded

Orphan grants Kirin Brewery marketing and distribution rights to Busulfex for Asia

Pharmaccine collaboration between Oxxon Pharmaccines and Ludwig Institute

Competitive metabotropic glutamate receptor antagonist with some selectivity for mglu5 subtype

ArQule and Acadia join forces in GPCR-targeted drug discovery

OSI Pharmaceuticals reviews progress during the year

Cubist completes enrollment in phase III skin & soft tissue infection trial

Highly selective tracer for mapping brain A2A receptors discovered by Kyowa Hakko

Merck KGaA establishes Merck Pharma in Italy through acquisition

Applied Molecular Evolution and Biosynexus to optimize antibacterial agent

Combination tgDCC-E1A/radiation therapy enters phase II

Meiji Milk and Takeda to codevelop MT-201 for treatment of cryptomeria pollinosis

Lilly and Sankyo to collaborate on CS-747 development

Advanced Magnetics submits sNDA for Feridex I.V. contrast agent

FDA approves Botox for cervical dystonia

R.W. Johnson seeks FDA approval for transdermal contraceptive

Celgene's NDA for d-MPH accepted for review by FDA

GlaxoSmithKline now listed on London and N.Y. stock exchanges

Otsuka reveals thiazole derivatives with potential broad therapeutic application

Takeda discloses compounds with potent adenosine A3 receptor-antagonist activity

Japan Science and Technology Corporation's unique compounds for diabetes and hypertension therapy

N-Aryl-alkylamides for CNS disorders claimed by Warner-Lambert

Arylamidines and cyclic amidines with broad clinical application reported by Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...